Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/8178
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKarabina, S. A. P.en
dc.contributor.authorElisaf, M.en
dc.contributor.authorBairaktari, E.en
dc.contributor.authorTzallas, C.en
dc.contributor.authorSiamopoulos, K. C.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:39:39Z-
dc.date.available2015-11-24T16:39:39Z-
dc.identifier.issn0014-2972-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/8178-
dc.rightsDefault Licence-
dc.subjectfamilial hypercholesterolaemiaen
dc.subjectlow-density lipoprotein subfractionsen
dc.subjectlysophosphatidylcholineen
dc.subjectoxidationen
dc.subjectplatelet-activating factor acetylhydrolaseen
dc.subjectcoronary-artery diseaseen
dc.subjecthuman-plasmaen
dc.subjectpaf-acetylhydrolaseen
dc.subjectendothelial-cellsen
dc.subjectdegrading acetylhydrolaseen
dc.subjectlipid-peroxidationen
dc.subjectcultured humanen
dc.subjectmodified ldlen
dc.subjectsusceptibilityen
dc.subjectatherogenesisen
dc.titleIncreased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondary<Go to ISI>://A1997XL84500012-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1046/j.1365-2362.1997.1570706.x/asset/j.1365-2362.1997.1570706.x.pdf?v=1&t=h0f7yesi&s=99fa2756da221c745476578a99d1dc4c587a3df2-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate1997-
heal.abstractPatients with heterozygous familial hypercholesterolaemia (FH) have elevated plasma concentrations of low-density lipoprotein (LDL) and develop premature atherosclerosis. There is increasing evidence that oxidative modification of LDL is important for the pathogenesis of atherosclerosis, and the LDL-associated platelet-activating factor acetylhydrolase (PAF-AH) seems to play a key role in LDL oxidation by hydrolysing the oxidized phospholipids of phosphatidylcholine (PC) and producing lysophosphatidylcholine (lyso-PC). We measured the total serum and high-density lipoprotein (HDL) levels of PAF-AH activity and studied the distribution of PAF-AH activity among three LDL subfractions isolated by gradient ultracentrifugation in 15 patients with heterozygous FH and 13 normolipidaemic control subjects. We also determined the lyse-PC production in each LDL subfraction during Cu2+-induced oxidation in vitro. The total serum PAF-AH activity in heterozygous FH patients was significantly higher than in control subjects, whereas the HDL-associated PAF-AH activity, expressed as a percentage of total serum PAF-AH activity, was significantly lower in the FH patients than in control subjects (13.9 +/- 6.6% vs. 30.6 +/- 4.4%, P < 0.001). Among the LDL subfractions, the PAF-AH activity in both normolipidaemic control subjects and FH patients, expressed as nmol mg(-1) protein min(-1), was significantly higher in the LDL3 subfraction (3.31 +/- 4.8 and 53.4 +/- 11.5 respectively) than in the LDL2 (18.6 +/- 5.3 and 26.8 +/- 10.4 respectively, P < 0.0001 for both comparisons) and LDL1 subfractions (5.1 +/- 1.5 and 7.8 +/- 2.6, respectively, P < 0.0001 for both comparisons). Additionally, the enzyme activity in each LDL subfraction of the heterozygous FH patients was significantly higher than in control subjects (P < 0.02 for LDL1, P < 0.03 for LDL2 and P < 0.0001 for LDL3). No difference was observed in the susceptibility to oxidation of each LDL subfraction among the heterozygous FH patients and the normolipidaemic control subjects. During oxidation, the PAF-AH activity decreased, whereas the lyse-PC levels significantly increased in all subfractions of both groups. The lyso-PC/sphingomyelin molar ratio in each LDL subfraction of the FH patients 3 h after the onset of the oxidation was significantly higher than in control subjects [0.38 +/- 0.05 and 0.27 +/- 0.04, respectively, for LDL1 (P < 0.006), 0.47 +/- 0.08 and 0.39 +/- 0.03, respectively, for LDL2 (P < 0.04), 0.55 +/- 0.11 and 0.42 +/- 0.06, respectively, for LDL3 (P < 0.02)]. Our results show that heterozygous FH patients exhibit higher PAF-AH activity than control subjects in all LDL subfractions, resulting in higher lyso-PC production during oxidation, which confers on these subfractions higher biological potency. This phenomenon, in combination with the diminished anti-atherogenic and antioxidant capability of HDL in these patients due to the relatively low HDL-cholesterol levels compared with LDL-cholesterol levels and, consequently, the relatively low HDL-associated PAF-AH activity, could contribute to the higher atherogenicity and incidence of coronary artery disease observed in FH patients.en
heal.journalNameEur J Clin Investen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Files in This Item:
File Description SizeFormat 
Karabina-1997-Increased activity o.pdf414.93 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons